Quantification With Lutetium-177 on Cadmium-Zinc-Telluride Camera 3D (QUADO)

Central Hospital, Nancy, France

Status: Completed

Conditions: Prostate Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT06783088

2024PI251

Details and patient eligibility

About

The main of this study is to demonstrate the feasibility of carrying out quantitative acquisitions regardless of the energy peak considered (113 keV (kiloelectronVolts) or 208 keV or a combination of the 2 energy peaks). A study on phantom will optimise the reconstruction parameters. These parameters will then be applied to a population of patients who have already benefited from a recording on a 3D CZT camera (retrospective data).

Full description

Lutetium 177 is a beta emitter - and is used in therapy. It also emits during its radioactive decay, two gamma photons of energy 113 and 208 keV allowing to produce images. The dosimetry committee of the European Association for Nuclear Medicine (EANM) recommends using only the peak at 208 keV to obtain so-called quantitative images using a conventional camera also called an Anger camera.

For several years, new semiconductor cameras (CZT cameras) have been available in nuclear medicine departments. They offer better performances particularly in terms of detection sensitivity and energy resolution. The nuclear medicine team has already carried out studies with Lutetium-177 with these semiconductor cameras on phantoms as well as dosimetry studies after treatment using Lutetium-177.

This study should demonstrate the feasibility of carrying out quantitative acquisitions regardless of the energy peak considered (113 keV or 208 keV or a combination of the 2 energy peaks). A study on phantom will optimise the reconstruction parameters. These parameters will then be applied to a population of patients who have already benefited from a recording on a 3D CZT camera (Retrospective data).

Enrollment: 20 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

It is a retrospective study and the criteria to collect the imaging are:

Inclusion Criteria:

Patients treated by at least one cure of lutetium vipivotide tetraxetan with imaging

Exclusion Criteria:

Patient having sent an objection to the use of their data